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Summary
Introduction:  The  goal  of  the  Quality  of  Literature  in  Arthroplasty  (QoLA)  project  launched  in
2009 was  to  compare  the  implant  results  from  clinical  studies  published  in  indexed  scientiﬁc
journals with  those  found  in  reference  national  registers.  The  potential  biases  in  the  chosen
articles (country  of  origin,  inventor  involved  in  study,  methodological  quality)  were  systemat-
ically analyzed  and  the  revisions  per  100  observed  component  years  (Revp100OCY)  index  was
calculated.  For  a  given  implant,  a  differential  factor  greater  than  3  between  the  Revp100OCY
index for  published  series  and  the  one  from  registers  was  considered  as  indicative  of  a  potential
selection (inventor)  or  publication  (conﬂict  of  interest)  bias.  Although  initially  performed  on
English publications,  this  methodology  was  subsequently  applied  to  French  publications  in  the
ﬁeld of  total  hip  arthroplasty  (THA).
Material  and  methods:  French  publications  indexed  in  Medline  (Rev  Chir  Orthop  and  Orthop
Trauma Surg  Res  since  2009)  were  analyzed.  These  studies  involved  implants  designed  in
France (ABGTM,  CorailTM stem,  CeraﬁtTM/OstealTM,  Bousquet)  or  that  were  used  worldwide
(OmniﬁtTM stem,  AlloclassicTM and  Charnley-type  or  Müller-type  implants).  The  articles  or
abstracts  selected  had  to  contain  sufﬁcient  information  (number  of  revisions,  number  of  cases
and/or revisions,  average  follow-up)  to  allow  the  Revp100OCY  index  to  be  calculated.
Results: Overall,  the  average  Revp100OCY  index  for  THA  series  published  in  French  was  0.76,
which is  consistent  with  the  worldwide  average  of  1.29.  For  the  ABGTM System,  the  Revp100OCY
∗ Corresponding author.
E-mail address: c.delaunay@clinique-yvette.com (C. Delaunay).
1877-0568/$ – see front matter © 2013 Elsevier Masson SAS. All rights reserved.
http://dx.doi.org/10.1016/j.otsr.2013.02.001
258  C.  Delaunay  et  al.
index  was  1.5,  which  was  higher  than  register  data  (0.77).  Cemented  Charnley-type  stems
had a  Revp100OCY  index  of  1.68  (register  0.64)  and  low  friction  arthroplasty  type  THA  had  a
Revp100OCY  index  of  0.59  (register  0.33).  The  Revp100OCY  index  was  slightly  lower  relative  to
register data  for  the  Müller  THA  (0.22  versus  0.33),  CorailTM stem  (0.1  versus  0.24),  OmniﬁtTM
(0.26  versus  0.37)  and  AlloclassicTM (0.21  versus  0.49).  Other  implants  without  comparable
register data  had  a  relatively  high  Revp100OCY  index:  1.2  for  the  Bousquet  dual  mobility  cup
and 1.35  for  the  OstealTM/CeraﬁtTM hybrid  system.
Conclusions:  The  few  studies  published  in  French  include  only  a  limited  number  of  cases,  but
their follow-up  is  long  and  the  revision  rate  consistent  with  register  data.  There  is  no  indication
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The  aforementioned  methodology  for  international  publica-of any  type  of  bias  in  French
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here  are  two  major  datasets  available  for  the  assessment
f  implants  or  surgical  techniques:  clinical  studies  that  have
een  published  in  peer-reviewed,  scientiﬁc  journals  and
ational,  regional  or  multicenter  arthroplasty  registers.
Clinical  studies  are  observational  and  based  on  a  limited
umber  of  cases  (cohort).  They  tend  to  extrapolate  the
esults  from  a  small  group  of  studied  patients/implants  to
he  entire  patient  population.  It  is  well  known  that  certain
iases  occurring  during  the  conduct  of  a  clinical  trial  can  sig-
iﬁcantly  impact  the  conclusions:  patient  selection,  study
esign  (retrospective,  prospective),  concentration  of  inter-
sted  parties  (designers  and  manufacturers).  Consequently,
he  ability  to  reproduce  the  results  in  the  general  population
as  been  questioned.  This  problem  is  clearly  found  within
he  scientiﬁc  selection  of  various  top  arthroplasty  journals.
he  European  Arthroplasty  Register  (EAR)  group  has  already
ecognized  the  accumulation  of  non-reproducible  results  in
tudies  published  in  two  North  American  journals  (Clinical
rthopaedics  and  Related  Research  and  Journal  of  Arthro-
lasty)  that  publish  most  of  the  arthroplasty-related  studies.
hus,  76%  (CORR)  and  63%  (JOA)  of  all  published  cases  in
hese  two  journals  were  from  the  inventors  of  the  implants
n  question  (unpublished  EAR  data).
Conversely,  epidemiological  registers  tend  to  collate
ost  cases  of  primary  arthroplasty  with  the  primary  failure
riterion  being  the  revision  of  part  or  all  of  the  components.
o  encourage  participation  while  trying  to  be  as  complete  as
ossible,  the  documentation  burden  must  not  be  too  heavy
nd  must  focus  on  the  essential  points:  surgical  approach,
mplant  type  and  ﬁxation  method,  bearings  used,  compar-
tive  survival  analysis,  etc.  Registers  reﬂect  on  the  current
ractice  in  the  country  or  region  in  which  the  data  are  col-
ected.  Because  of  the  shear  mass  of  data  included,  they
rown  out  the  results  from  series  involving  implant  inven-
ors.
The  Quality  of  Literature  in  Arthroplasty  (QoLA)  project
as  launched  by  the  EAR  group  in  2009  [1].  The  goal  was
o  compare  implant  results  between  clinical  studies  pub-
ished  in  indexed  journals  and  data  provided  by  high-level
ational  registers.  Although  survival  analysis  is  the  gold
tandard  to  express  and  compare  implant-related  results,
s  in  all  Scandinavian  registers,  they  require  the  implant
ata  to  be  matched  with  vital  records  data  for  the  death
f  an  implanted  patient  to  be  automatically  detected  [2].
his  prerequisite  to  establishing  survival  curves  is  not  legally
easible  in  a  large  number  of  developed  countries.  Thus
t
h
ontiﬁc  publications  relative  to  the  reproducibility  of  THA  results.
rights  reserved.
nother  criterion  was  needed  to  compare  the  implant  results
rom  one  register  to  another,  and  between  clinical  studies
nd  registers.  The  EAR  group  decided  to  use  the  ‘‘revision
er  100  observed  component  years’’  (Revp100OCY)  index.
nitially,  this  index  was  developed  in  Great  Britain  in  the
950s  for  epidemiological  studies  on  smoking  [3]  and  was
ntroduced  in  orthopedics  by  the  Australian  Joint  Replace-
ent  Registry  [4].  The  formula  for  the  calculation  is:
Revp100OCY  index  =  (Number  of  revisions  ×  100)  /  (Num-
er  of  primary  THA  reviewed  ×  average  follow-up).
One  of  the  ﬁrst  steps  of  the  QoLA  project  was  to  apply  this
ormula  to  as  many  published  hip  arthroplasty  clinical  stud-
es  as  possible.  Articles  written  in  English  were  identiﬁed
n  Medline-indexed  journals  and  through  a  manual  search.
he  selected  publications  had  to  contain  the  information
eeded  to  calculate  the  revision  index  and  analyze  poten-
ial  biases:  country  of  origin,  inventor  involved  in  study  and
ethodological  quality.
Also,  in  registers  comparing  results  from  various  teams
nd/or  facilities  (Sweden,  Denmark),  the  best  differ  by  a
actor  of  3  among  each  other.  Based  on  this  observation,  the
AR  group  chose  to  use  a differential  factor  greater  than  3
s  the  threshold  level  to  indicate  a  potential  bias  between
linical  study  results  and  register  results.  In  other  words,
hen  the  Revp100COA  index  for  a  well-deﬁned  implant  is  at
east  3  times  lower  in  a  clinical  study  than  the  index  cal-
ulated  from  registers  where  this  same  implant  is  present,
he  clinical  study  results  are  considered  as  non-reproducible
y  all  standard  orthopedic  surgeons.  This  can  either  be
he  result  of  the  inventor’s  facility  having  special  exper-
ise,  or  a  methodological  bias  or  conﬂict  of  interest  being
resent.  This  method  was  applied  on  a  very  large  scale  to
ata  available  in  the  most  recent  reports  of  the  six  largest
egisters  (Sweden,  Denmark,  Norway,  Finland,  Australia  and
ew  Zealand).  In  terms  of  total  hip  arthroplasty  (THA),
9,231  revisions  were  identiﬁed  from  a  total  of  689,608  THA
ollected  at  an  average  follow-up  of  8.9  years.  The  aver-
ge  Revp100COA  index  was  calculated  to  be  1.29  (range
.28—1.30),  which  serves  as  the  worldwide  reference  index
5].
aterial and methodsions  was  applied  to  French  publications  in  the  ﬁeld  of  total
ip  arthroplasty  through  a  search  for  studies  published  in  the
nly  French,  Medline-indexed  journal,  Revue  de  Chirurgie
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Orthopédique  (RCO),  which  became  Orthopaedics  &  Trau-
matology  Surgery  and  Research  (OTSR) in  2009.  Only  articles
published  since  2000  were  included,  as  were  peer-reviewed
conference  abstracts  (mostly  for  the  annual  meeting  of
the  French  Orthopedics  and  Trauma  Surgery  Society  [SoF-
COT])  that  had  the  information  needed  to  calculate  the
Revp100OCY  index  (number  of  cases  actually  followed  at
the  average  follow-up  and  number  of  revisions)  and  had  an
average  follow-up  of  at  least  eight  years.  The  selection  was
focused  on  hip  implants  designed  in  France  (ABGTM system,
CorailTM femoral  stem,  CeraﬁtTM cup-OstealTM stem,  Bous-
quetdual  mobility  cup),  along  with  implants  used  worldwide
such  as  OmniﬁtTM stems,  Zweymüller-AlloclassicTM or  Müller
and  Charnley-Low  Friction  Arthroplasty  (LFA)  implants.  In
the  end,  eight  articles  and  six  abstracts  were  retained.
The  Revp100OCY  index  was  calculated  for  each  implant
and  compared  to  the  information  available  in  the  refer-
ence  national  registers.  Since  many  of  the  implants  used  in
France  were  not  present  in  the  historical  Swedish,  Finnish
or  British  registers,  most  of  the  comparative  data  came
from  the  Australian,  Norwegian  and  New  Zealand  regis-
ters.  When  the  clinical  and  register  data  could  be  compared
for  a  given  implant,  the  differential  factor  was  calculated
(ratio  between  the  highest  and  lowest  index).  A  differential
greater  than  3  was  considered  as  an  indicator  of  a  potentially
b
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Table  1  Comparison  of  the  revision  per  100  observed  compone
studies.
Implant  Average
follow-up
Nu
pri
ABGTM I  and  II  system
Australian  and  New  Zealand  registers  [4,6]  6.9  37
RCO/OTSR [7,8]  10  1
CorailTM stem
Norwegian  register  [9]  6.8  51
RCO/OTSR [10,11]  12  1
Charnley stem
Danish  register  [12]  5.8  38
RCO/OTSR [13] 10  1
Charnley-type  THA
New  Zealand  register  [6]  8  4
RCO/OTSR [14]  <  50  14.2  2
OmniﬁtTM stem
Norwegian  register  [9]  4.5  2
RCO/OTSR [15]  <  50  8.2  4
Alloclassic-SLTM stem
Norwegian  register  [9]  8.3  5
RCO/OTSR [16,17]  8.8  4
Cemented Müller  THA
New  Zealand  register  [6]  7  13
RCO/OTSR [18]  10  
CeraﬁtTM-OstealTM RCO  [19—21] 9.1 2
Bousquet cup  RCO  [22] 10.7 3259
orrisome  discordance  between  the  two  types  of  evalua-
ions.
esults
he  comparison  between  the  data  from  articles  and
bstracts  published  in  RCO-OTSR  and  those  found  in  the
eference  registers  is  summarized  in  Table  1.
For  the  ABGTM implant  system,  the  French  studies
onsisted  of  small  series  for  the  entire  system,  with  no  clear
election  of  the  revised  implant(s).  The  Revp100OCY  index
as  0.77  in  the  Australian  and  New  Zealand  registers  [4,6].
his  is  better  than  in  the  French  series,  [1,5]  despite  the
act  that  one  of  series  was  published  by  an  inventor  [7,8].
For  the  CorailTM system,  the  Revp100OCY  index  was
xcellent  (0.25  with  6.8  years  average  follow-up)  in  the  Nor-
egian  register  [9].  It  was  even  better  (0.1)  in  the  French
ublications,  with  one  involving  an  inventor,  despite  the  fact
hat  the  average  follow-up  was  longer  (12  years)  [10,11].
The  results  with  cemented  Charnley  stems  (0.64)  were
etter  in  the  Danish  register  [12], than  the  series  (1.68)  pub-
ished  in  RCO-OTSR  that  came  from  a  Norwegian  group  [13].
s  for  the  Charnley-Kerboull  or  Charnley-type  cemented
HA,  the  results  were  comparable:  0.33  in  the  New  Zealand
nt  years  index  between  international  registers  and  French
mber  of
mary
Number  of
revisions
Observed
component
years  (OCY)
Revp100COA
index
(differential)
87  201  26,107  0.77
65  25  1665  1.5  (1.9)
30  83  34,884  0.24
83  2  2196  0.1  (2.4)
56  976  26,221  0.64
85  31  1850  1.68  (2.6)
56  12  3667  0.33
15  18  3053  0.59  (1.8)
99  5  1345  0.37
24  9  3490  0.26  (1.4)
12  21  4249  0.49
32  8  3796  0.21  (2.3)
53  32  9570  0.33
90  2  900  0.22  (1.5)
99  37  2735  1.35
64  47  3895  1.2
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egister  [6]  and  0.59  in  a  series  published  by  an  inventor
14].
With  the  OmniﬁtTM and  Alloclassic-SLTM stems,  the
ndexes  were  good  overall  in  the  Norwegian  register  [9]  and
ven  better  in  the  French  studies,  despite  none  of  the  inven-
ors  having  been  involved  [15—17].  This  was  similar  to  the
emented  Müller  implant  system  with  a  low  index  (0.31)
n  the  New  Zealand  register  [6]  and  one  published  study  in
CO-OTSR  (0.22)  [18].  The  differential  factor  between  the
evp100OCY  clinical  and  register  indexes  varied  from  1.4  for
he  OmniﬁtTM stem  to  2.6  for  the  Charnley  stem  and  never
ttained  the  threshold  value  of  3.
For  other  implants  invented  in  France  but  with  no  compa-
able  register  data,  the  cohorts  were  relatively  small  for  a
ollow-up  of  more  than  nine  years.  The  Revp100OCY  index
as  at  the  higher  end:  1.35  for  the  Ceraver-OstealTM implant
ith  an  alumina-alumina  bearing  and  a  study  involving  the
nventors  [19—21]  and  1.2  for  the  original  Bousquet  dual
obility  cup  [22].
Table  2  summarizes  the  results  from  all  the  French  studies
elected  [23].  The  global  revision  index  was  0.76,  which  is
onsistent  but  slightly  lower  than  the  worldwide  average
f  1.29  for  THA.  Six  of  the  clinical  studies  evaluated  had
ohorts  of  patients  below  50  years  of  age  [8,10,14,15,20,21].
Other  clinical  studies  involving  speciﬁc  hip  implants  were
ublished  in  RCO-OTSR, but  the  follow-up  was  too  short  to
e  included  in  this  evaluation.  For  example,  the  Revp100OCY
ndex  was  low  (0.35)  for  the  EvoraTM cup  (no  conﬂict  of
nterest  declared)  and  quite  low  (0.16)  for  the  SPSTM stem
n  a  single-surgeon  series  where  two  of  the  authors  were
fﬁliated  with  the  manufacturer  [24,25].  There  is  currently
o  data  available  in  the  reference  registers  for  the  two
mplants.
iscussion
n  his  thesis,  Havelin  determined  that  a  prospective  study
ould  have  to  include  13,474  cases  to  show  a  1%  difference
n  revisions  between  two  implants  with  the  usual  statistical
tandards  (95%  conﬁdence  interval  and  80%  power)  [26].  It  is
eadily  apparent  that  clinical  studies  with  generally  smaller
ohorts  are  regularly  at  fault  in  terms  of  statistical  power.
ence  the  importance  of  registers.  Because  of  the  large
umbers,  sufﬁcient  statistical  power  exists  to  show  signif-
cant  differences  in  the  performance  of  various  implants.Following  the  efforts  initiated  in  Sweden  in  the  early
970s,  a  few  developed  countries  now  have  national
rthroplasty  registers  that  are  effective  because  they  are
ompulsory  (Scandinavian  countries,  Australia,  England  and
t
S
a
e
Table  2  Comparison  of  the  revisions  per  100  observed  compone
register data.
Implant  Average
follow-up
Number  of
primary
N
r
RCO/OTSR  articles  10  2357  
Worldwide THA  registers  8.9  689,608  7
SoFCOT THA  register  (2012)  3.42  11,116  C.  Delaunay  et  al.
ales,  New  Zealand).  These  registers  provide  a  good  view  of
he  practices  and  comparative  results  for  the  implants  used
n  the  corresponding  region.  Given  the  variations  in  the  mar-
et  from  one  country  or  continent  to  another,  the  current
rend  is  to  group  the  register  results  within  international
rganizations  such  as  EAR  in  Europe  and  the  International
onsortium  of  Orthopaedic  Registries  (ICOR)  in  the  United
tates  [27].  But  several  large  developed  countries  only  have
ither  regional  (Italy,  Spain)  or  multicenter  (France,  United
tates)  registers  with  participation  that  is  voluntary  and  not
equired  by  health  authorities;  other  is  still  being  launched
Germany,  Austria).
The  lack  of  a  national  register  is  even  more  harmful  in
he  United  States  because  the  arthroplasty  surgery  activity
s  intense  and  the  sheer  number  of  publications  resulting
rom  this  activity  has  a  signiﬁcant  inﬂuence  throughout  the
orld.  The  impact  of  the  work  of  American  inventors  was
evealed  by  the  EAR  team  [28].  Overall,  for  implants  devel-
ped  in  the  USA,  48.2%  of  primary  implantations  and  47.1%
f  observed  component  years  were  reported  by  authors  afﬁl-
ated  with  the  inventor(s).  If  we  compare  this  with  implants
eveloped  in  continental  Europe,  only  10.2%  of  implanta-
ions  and  15.9%  of  observed  component  years  were  reported
y  teams  comprising  the  inventor(s).
The  methodology  developed  by  the  QoLA  group  can  also
e  used  with  a  speciﬁc  implant  when  data  from  clinical  stud-
es  is  or  becomes  conﬂicting.  A  multiregister  analysis  was
onducted  on  the  SL-PlusTM stem  based  on  a  request  from
ts  manufacturer  (Smith  &  Nephew,  Memphis,  TN)  to  improve
he  worldwide  evaluation  of  the  product  and  get  away  from
otential  publication  biases  [29].  This  study  showed  that  the
uality  of  the  implant  was  good  in  the  registers  and  that  the
oor  published  results  were  in  fact  related  to  the  bearings
sed  (SikometTM).
Calculating  the  annual  revision  index  per  100  observed
omponent  years  allows  a comparison  to  be  made  (bench
arking)  between  various  implants  without  needing  to  be
nformed  about  patient  deaths.  This  index  was  chosen  to
uantify  and  compare  arthroplasty  results  in  the  registers
f  most  of  the  countries  grouped  within  the  EAR,  including
he  SoFCOT  multicenter  THA  register.  In  2012,  the  overall
evp100OCY  index  was  0.34  with  an  average  follow-up  of
.4  years  (Table  2).  This  was  less  than  half  the  average  index
0.76)  calculated  from  studies  published  in  RCO-OTSR,  which
ad  a  longer  follow-up  (10  years).
One  of  the  weak  points  of  the  current  study  is  that  part  of
he  data  was  taken  from  abstracts  presented  at  the  annual
oFCOT  meeting;  these  do  not  have  the  same  scientiﬁc  value
s  published  studies  that  have  met  the  requirements  of  an
ditorial  board.  However,  all  the  included  abstracts  had
nt  years  index  between  studies  published  in  RCO/OTSR  and
umber  of
evisions
Observed  component
years  (OCY)
Average
Revp100COY  index
179  23,580  0.76
9,231  6,137,511  1.29
130  38,017  0.34
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been  selected  after  peer-review,  all  the  implants  in  ques-
tion  have  been  the  subject  of  numerous  published  scientiﬁc
studies  internationally  and  the  three  data  elements  used
(number  of  THA  actually  analyzed  at  the  average  follow-up,
follow-up  of  more  than  8  years,  and  number  of  revisions)  are
in  themselves  not  scientiﬁcally  open  to  criticism.
In  fact,  the  French  inventors  and  users  of  several  implants
available  in  France  have  not  only  published  their  results  in
their  native  language,  but  also  quite  often  in  international
English-language  journals  while  seeking  a  broader  audience.
These  English  publications  have  probably  contributed  to
some  French  implants  breaking  into  foreign  markets  and
appearing  in  the  national  registers  of  certain  countries.  This
is  especially  the  case  for  the  ABGTM implants  and  CorailTM
stem,  which  are  found  in  the  reference  Danish,  Norwegian,
Australian  and  New  Zealand  registers.
Nevertheless,  since  the  English  indexed  version  of  RCO
was  created  in  2009  (OTSR),  the  impact  factor  has  greatly
increased  (from  0.3  in  2008  to  0.943  in  2012),  including  an
81%  increase  in  the  past  two  years.  We  can  speculate  that
this  success  may  lead  French  groups  to  publish  in  their  native
language  more  often,  while  still  enjoying  the  beneﬁts  of
reaching  an  international  audience  when  their  study  reports
are  translated  into  English  for  publication  in  OTSR.
Conclusions
There  are  very  few  hip  arthroplasty  studies  published  in
French  literature.  They  have  small  cohorts  but  a  longer
follow-up  than  those  collected  in  the  reference  registers.
The  Revp100OCY  index  values  were  either  higher  or  lower
(but  never  more  than  3  times)  than  those  found  in  registers,
including  studies  involving  the  French  implant  inventors.  The
ﬁnding  that  the  French  revision  indexes  were  often  higher
than  those  in  registers  is  more  likely  an  indicator  of  qual-
ity,  probably  related  to  the  longer  follow-up  in  the  French
studies.  In  light  of  this  work,  these  are  no  indications  of  any
recurring  bias  in  French  scientiﬁc  publications  that  would
lead  one  to  question  the  reproducibility  of  results  of  total  hip
arthroplasty  and  the  quality  of  the  average  standard  service
provided  to  patients.
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